Single User
£3698
PDF
70 pages

Atopic Dermatitis Forecast in 17 Major Markets 2015-2025


Atopic Dermatitis, also known as eczema, is a common disorder of the epidermis of the skin causing dryness, itchiness, red rashes, inflammation, sores and blisters. It occurs mostly in early childhood and can develop from exposure to allergens and irritants, such as dust mites, pollen, peanuts and so forth. The prognosis for most patients is improvement in symptoms, and by adulthood it may disappear altogether.

This report provides the current prevalent population for Atopic Dermatitis across 17 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Turkey, Mexico, Canada, Australia, South Africa, Poland, Russian Federation and China) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of severity, location and IgE levels of Atopic Dermatitis, to name a few. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Atopic Dermatitis have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Atopic Dermatitis include:

  • Asthma
  • Rhinitis
  • Allergies (Food or Inhalant-related)
  • Rashes
  • Eczemic lesions

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global Atopic Dermatitis’s market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Atopic Dermatitis and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Atopic Dermatitis’s prevalent population.
  • Identify sub-populations within Atopic Dermatitis which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Atopic Dermatitis patients.
Table of Contents
  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors and Prevention
  • Diagnosis of the Disease
  • Variation by Geography/ Ethnicity
  • Disease Prognosis and Clinical Course
  • Key Co-Morbid Conditions / Features associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Prevalence for Atopic Dermatitis
  • Main Features of Atopic Dermatitis Patients
    • Severity of Atopic Dermatitis
    • Total IgE Levels
    • Location of Symptoms
    • Atopic Syndrome Inheritance
  • Co-morbid Conditions Associated with Atopic Dermatitis
    • Respiratory Conditions in Atopic Dermatitis
    • Skin-related Conditions in Atopic Dermatitis
    • Allergy Conditions in Atopic Dermatitis
  • Abbreviations used in the Report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix
List of Tables
  • Prevalence of AD, total (000s)
  • Prevalence of AD, males (000s)
  • Prevalence of AD, females (000s)
  • Severity of AD, total (000s)
  • Flare frequency in the past 12 months in patients with AD, total (000s)
  • IgE levels (kU/L) of patients with AD, total (000s)
  • Symptom location of AD, total (000s)
  • AD patients with parents suffering from atopy, total (000s)
  • Prevalence of Asthma in AD patients, total (000s)
  • Prevalence of Allergic Rhinitis in AD patients, total (000s)
  • Prevalence of red or inflamed rashes in AD patients, total (000s)
  • Prevalence of excessive dry/scaling skin in patients with AD, total (000s)
  • Prevalence of psoriasis in AD patients, total (000s)
  • Prevalence of filaggrin mutation in AD patients, total (000s)
  • Prevalence of peanut allergy in AD patients, total (000s)
  • Prevalence of house dust mite allergy in AD patients, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA prevalence of AD by 5-yr age cohort, males (000s)
  • USA prevalence of AD by 5-yr age cohort, females (000s)
  • France prevalence of AD by 5-yr age cohort, males (000s)
  • France prevalence of AD by 5-yr age cohort, females (000s)
  • Germany prevalence of AD by 5-yr age cohort, males (000s)
  • Germany prevalence of AD by 5-yr age cohort, females (000s)
  • Italy prevalence of AD by 5-yr age cohort, males (000s)
  • Italy prevalence of AD by 5-yr age cohort, females (000s)
  • Spain prevalence of AD by 5-yr age cohort, males (000s)
  • Spain prevalence of AD by 5-yr age cohort, females (000s)
  • United Kingdom prevalence of AD by 5-yr age cohort, males (000s)
  • United Kingdom prevalence of AD by 5-yr age cohort, females (000s)
  • Brazil prevalence of AD by 5-yr age cohort, males (000s)
  • Brazil prevalence of AD by 5-yr age cohort, females (000s)
  • Japan prevalence of AD by 5-yr age cohort, males (000s)
  • Japan prevalence of AD by 5-yr age cohort, females (000s)
  • India prevalence of AD by 5-yr age cohort, males (000s)
  • India prevalence of AD by 5-yr age cohort, females (000s)
  • Turkey prevalence of AD by 5-yr age cohort, males (000s)
  • Turkey prevalence of AD by 5-yr age cohort, females (000s)
  • Mexico prevalence of AD by 5-yr age cohort, males (000s)
  • Mexico prevalence of AD by 5-yr age cohort, females (000s)
  • Canada prevalence of AD by 5-yr age cohort, males (000s)
  • Canada prevalence of AD by 5-yr age cohort, females (000s)
  • Australia prevalence of AD by 5-yr age cohort, males (000s)
  • Australia prevalence of AD by 5-yr age cohort, females (000s)
  • South Africa prevalence of AD by 5-yr age cohort, males (000s)
  • South Africa prevalence of AD by 5-yr age cohort, females (000s)
  • Poland prevalence of AD by 5-yr age cohort, males (000s)
  • Poland prevalence of AD by 5-yr age cohort, females (000s)
  • Russia prevalence of AD by 5-yr age cohort, males (000s)
  • Russia prevalence of AD by 5-yr age cohort, females (000s)
  • China prevalence of AD by 5-yr age cohort, males (000s)
  • China prevalence of AD by 5-yr age cohort, females (000s)
Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Poland, Russian Federation, South Africa, Spain, Turkey, United Kingdom, United States of America